{"disease":{"id":"oropharyngeal-squamous-cell-carcinoma","name":"oropharyngeal squamous cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05050162","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":1714,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT05973487","title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":840,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04255849","title":"Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT06771674","title":"Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":662,"lead_sponsor_name":"Hookipa Biotech GmbH","has_results":false},{"nct_id":"NCT01810913","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":613,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05541016","title":"De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":455,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07441681","title":"Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":454,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06356272","title":"Oropharynx (OPX) Biomarker Trial","phase":"","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01893307","title":"Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":440,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05063552","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00588770","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":403,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03952585","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":384,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05524025","title":"The SPOT-HPV Study","phase":"","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03323463","title":"Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":316,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05721755","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":290,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT06138483","title":"A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse","phase":"","overall_status":"UNKNOWN","enrollment_count":267,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT05539638","title":"The Role of Circulating Tumour DNA in Head and Neck Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT05333523","title":"Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":242,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06592716","title":"Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03258554","title":"Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01855451","title":"Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":189,"lead_sponsor_name":"Trans Tasman Radiation Oncology Group","has_results":false},{"nct_id":"NCT02734537","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":189,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04671667","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07195734","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05075980","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06589804","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06115772","title":"Prospective Assessment of HPV Associated Anogenital Pathology in Female Patients and Female Partners of Patients With Confirmed HPV Associated Oropharyngeal Carcinoma, PAP-OP Study","phase":"","overall_status":"RECRUITING","enrollment_count":154,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04900623","title":"Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":145,"lead_sponsor_name":"Jonathan Schoenfeld, MD, MPH","has_results":false},{"nct_id":"NCT06055868","title":"People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity","phase":"","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03410615","title":"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":129,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT01064479","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06662058","title":"Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation","phase":"NA","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT07513324","title":"Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":116,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02984410","title":"Study Assessing The \"Best of\" Radiotherapy vs the \"Best of\" Surgery in Patients With Oropharyngeal Carcinoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":112,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT06009861","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Peking University Hospital of Stomatology","has_results":false},{"nct_id":"NCT06701058","title":"Active MMP-8 in Oral Fluid for the Detection of Oral and Oropharyngeal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":false},{"nct_id":"NCT05714657","title":"Shortened Course Adjuvant Radiotherapy Following TORS","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT06730412","title":"ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Massachusetts Eye and Ear Infirmary","has_results":false},{"nct_id":"NCT05108870","title":"TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":98,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT06532279","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT04260126","title":"Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"PDS Biotechnology Corp.","has_results":false},{"nct_id":"NCT06578871","title":"Surgery and Reducing Ionizing Radiation of the Unknown Primary","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT05278039","title":"Training Swallowing Initiation During Expiration","phase":"NA","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT07457099","title":"Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT01932697","title":"Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03978689","title":"A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Cue Biopharma","has_results":false},{"nct_id":"NCT03422536","title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT07209189","title":"Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}